文献速递脑血管病认知障碍与痴呆

有症状脑小血管病患者的单硝酸异山梨酯与西洛他唑治疗:腔隙性干预试验-2(LACI-2)随机临床试验

Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2023-01-01

LACI-2 是一项在26家英国医院开展的前瞻性、开放标签、盲法终点、2×2析因随机临床试验,计划纳入400例,实际纳入363例(90.8%)腔隙性缺血性卒中患者,12个月随访保留358例(98.6%)。单硝酸异山梨酯(ISMN)降低复发性卒中(aOR 0.23,95%CI 0.07-0.74;P=0.01)和认知障碍(aOR 0.55,95%CI 0.36-0.86;P=0.008);西洛他唑降低依赖(aHR 0.31,95%CI 0.14-0.72;P=0.006);联合治疗降低复合终点(aHR 0.58,95%CI 0.36-0.92;P=0.02)。

要点

  • LACI-2试验达到招募可行性目标,12个月保留率98.6%,药物耐受性和安全性良好。
  • 单硝酸异山梨酯降低复发性卒中和认知障碍,西洛他唑降低依赖,联合治疗改善复合终点和生活质量。
  • 作者认为两种药物均应在大型3期试验中进一步验证。

核心结论

  • LACI-2试验可行,单硝酸异山梨酯和西洛他唑耐受性良好且安全。
  • 这些药物可能减少腔隙性卒中后的复发性卒中、依赖和认知障碍,并可能预防脑小血管病的其他不良结局。
  • 作者认为两种药物均应在大型3期试验中进一步验证。

研究设计与样本

  • 研究者发起的开放标签、盲法终点、2×2析因随机临床试验(LACI-2),计划从26家英国医院卒中中心招募400例,实际纳入363例(90.8%),12个月随访。
  • 纳入标准为临床腔隙性缺血性卒中、生活独立、年龄>30岁、脑影像学 compatible、有同意能力、无研究药物禁忌证或适应证。
  • 患者随机接受单硝酸异山梨酯(40-60 mg/d)、西洛他唑(200 mg/d)、单硝酸异山梨酯-西洛他唑联合(分别为40-60和200 mg/d)或不接受研究药物,所有患者均接受指南推荐的卒中预防治疗。

主要发现

  • 363例纳入者中位年龄64岁(IQR 56.0-72.0),男性251例(69.1%),卒中至随机化中位时间79天(IQR 27.0-244.0)。
  • 12个月时358例(98.6%)保留在研究中,272例中257例(94.5%)服用至少50%的分配药物。
  • 与未接受相应药物的患者相比,单硝酸异山梨酯(aHR 0.80,95%CI 0.59-1.09;P=0.16)或西洛他唑(aHR 0.77,95%CI 0.57-1.05;P=0.10)单药均未降低297例患者的复合结局。
  • 单硝酸异山梨酯降低353例患者的复发性卒中(aOR 0.23,95%CI 0.07-0.74;P=0.01)和308例患者的认知障碍(aOR 0.55,95%CI 0.36-0.86;P=0.008);西洛他唑降低320例患者的依赖(aHR 0.31,95%CI 0.14-0.72;P=0.006)。
  • 联合治疗在153例患者中降低复合终点(aHR 0.58,95%CI 0.36-0.92;P=0.02)、依赖(aOR 0.14,95%CI 0.03-0.59;P=0.008)和任何认知障碍(aOR 0.44,95%CI 0.23-0.85;P=0.02),并改善生活质量(校正均数差0.10,95%CI 0.03-0.17;P=0.005);无安全性问题。

临床怎么用

  • 原文未据此给出临床推荐;作者认为单硝酸异山梨酯和西洛他唑可能减少腔隙性卒中后的复发性卒中、依赖和认知障碍,并可能预防脑小血管病的其他不良结局。
  • 作者建议两种药物均应在大型3期试验中进一步验证。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cerebral small vessel disease (cSVD) is a common cause of stroke (lacunar stroke), is the most common cause of vascular cognitive impairment, and impairs mobility and mood but has no specific treatment. OBJECTIVE: To test the feasibility, drug tolerability, safety, and effects of 1-year isosorbide mononitrate (ISMN) and cilostazol treatment on vascular, functional, and cognitive outcomes in patients with lacunar stroke. DESIGN, SETTING, AND PARTICIPANTS: The Lacunar Intervention Trial-2 (LACI-2) was an investigator-initiated, open-label, blinded end-point, randomized clinical trial with a 2 × 2 factorial design. The trial aimed to recruit 400 participants from 26 UK hospital stroke centers between February 5, 2018, and May 31, 2021, with 12-month follow-up. Included participants had clinical lacunar ischemic stroke, were independent, were aged older than 30 years, had compatible brain imaging findings, had capacity to consent, and had no contraindications to (or indications for) the study drugs. Data analysis was performed on August 12, 2022. INTERVENTIONS: All patients received guideline stroke prevention treatment and were randomized to ISMN (40-60 mg/d), cilostazol (200 mg/d), ISMN-cilostazol (40-60 and 200 mg/d, respectively), or no study drug. MAIN OUTCOMES: The primary outcome was recruitment feasibility, including retention at 12 months. Secondary outcomes were safety (death), efficacy (composite of vascular events, dependence, cognition, and death), drug adherence, tolerability, recurrent stroke, dependence, cognitive impairment, quality of life (QOL), and hemorrhage. RESULTS: Of the 400 participants planned for this trial, 363 (90.8%) were recruited. Their median age was 64 (IQR, 56.0-72.0) years; 251 (69.1%) were men. The median time between stroke and randomization was 79 (IQR, 27.0-244.0) days. A total of 358 patients (98.6%) were retained in the study at 12 months, with 257 of 272 (94.5%) taking 50% or more of the allocated drug. Compared with those participants not receiving that particular drug, neither ISMN (adjusted hazard ratio [aHR], 0.80 [95% CI, 0.59 to 1.09]; P = .16) nor cilostazol (aHR, 0.77 [95% CI, 0.57 to 1.05]; P = .10) alone reduced the composite outcome in 297 patients. Isosorbide mononitrate reduced recurrent stroke in 353 patients (adjusted odds ratio [aOR], 0.23 [95% CI, 0.07 to 0.74]; P = .01) and cognitive impairment in 308 patients (aOR, 0.55 [95% CI, 0.36 to 0.86]; P = .008). Cilostazol reduced dependence in 320 patients (aHR, 0.31 [95% CI, 0.14 to 0.72]; P = .006). Combination ISMN-cilostazol reduced the composite (aHR, 0.58 [95% CI, 0.36 to 0.92]; P = .02), dependence (aOR, 0.14 [95% CI, 0.03 to 0.59]; P = .008), and any cognitive impairment (aOR, 0.44 [95% CI, 0.23 to 0.85]; P = .02) and improved QOL (adjusted mean difference, 0.10 [95% CI, 0.03 to 0.17]; P = .005) in 153 patients. There were no safety concerns. CONCLUSIONS AND RELEVANCE: These results show that the LACI-2 trial was feasible and ISMN and cilostazol were well tolerated and safe. These agents may reduce recurrent stroke, dependence, and cognitive impairment after lacunar stroke, and they could prevent other adverse outcomes in cSVD. Therefore, both agents should be tested in large phase 3 trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03451591.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Wardlaw JM, Woodhouse LJ, Mhlanga II, et al. Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial. JAMA Neurol. 2023. PMID: 37222252. doi:10.1001/jamaneurol.2023.1526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。